128 related articles for article (PubMed ID: 10465403)
1. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
3. ACTA, a fluorescent analogue of thapsigargin, is a potent inhibitor and a conformational probe of skeletal muscle Ca2+-ATPase.
Procida K; Caspersen C; Kromann H; Christensen SB; Treiman M
FEBS Lett; 1998 Nov; 439(1-2):127-32. PubMed ID: 9849892
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
5. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
Furuya Y; Lundmo P; Short AD; Gill DL; Isaacs JT
Cancer Res; 1994 Dec; 54(23):6167-75. PubMed ID: 7954463
[TBL] [Abstract][Full Text] [Related]
6. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the interaction of thapsigargin with the conformational states of Ca(2+)-ATPase from skeletal sarcoplasmic reticulum.
Fortea MI; Soler F; Fernandez-Belda F
J Biol Chem; 2001 Oct; 276(40):37266-72. PubMed ID: 11445572
[TBL] [Abstract][Full Text] [Related]
8. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases.
Treiman M; Caspersen C; Christensen SB
Trends Pharmacol Sci; 1998 Apr; 19(4):131-5. PubMed ID: 9612087
[TBL] [Abstract][Full Text] [Related]
9. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin.
Andrews SP; Tait MM; Ball M; Ley SV
Org Biomol Chem; 2007 May; 5(9):1427-36. PubMed ID: 17464412
[TBL] [Abstract][Full Text] [Related]
10. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Denmeade SR; Isaacs JT
Cancer Biol Ther; 2005 Jan; 4(1):14-22. PubMed ID: 15662118
[TBL] [Abstract][Full Text] [Related]
11. Ca2+ pools and cell growth. Evidence for sarcoendoplasmic Ca2+-ATPases 2B involvement in human prostate cancer cell growth control.
Legrand G; Humez S; Slomianny C; Dewailly E; Vanden Abeele F; Mariot P; Wuytack F; Prevarskaya N
J Biol Chem; 2001 Dec; 276(50):47608-14. PubMed ID: 11606580
[TBL] [Abstract][Full Text] [Related]
12. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Vander Griend DJ; Antony L; Dalrymple SL; Xu Y; Christensen SB; Denmeade SR; Isaacs JT
Mol Cancer Ther; 2009 May; 8(5):1340-9. PubMed ID: 19417145
[TBL] [Abstract][Full Text] [Related]
13. Thapsigargin, Inhibitor of Sarco-Endoplasmic Ca
Kotnova AP; Lyanova BM; Dukhanina EA; Portseva TN; Ilyin YV; Georgieva SG; Stepchenko AG; Pankratova EV
Dokl Biochem Biophys; 2019 May; 486(1):181-183. PubMed ID: 31367816
[TBL] [Abstract][Full Text] [Related]
14. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP.
Gong Y; Blok LJ; Perry JE; Lindzey JK; Tindall DJ
Endocrinology; 1995 May; 136(5):2172-8. PubMed ID: 7720667
[TBL] [Abstract][Full Text] [Related]
15. Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin.
Søhoel H; Liljefors T; Ley SV; Oliver SF; Antonello A; Smith MD; Olsen CE; Isaacs JT; Christensen SB
J Med Chem; 2005 Nov; 48(22):7005-11. PubMed ID: 16250659
[TBL] [Abstract][Full Text] [Related]
16. Ca2+ increase and Ca(2+)-influx in human tracheal smooth muscle cells: role of Ca2+ pools controlled by sarco-endoplasmic reticulum Ca(2+)-ATPase 2 isoform.
Amrani Y; Magnier C; Enouf J; Wuytack F; Bronner C
Br J Pharmacol; 1995 Aug; 115(7):1204-10. PubMed ID: 7582546
[TBL] [Abstract][Full Text] [Related]
17. Ethanol has different effects on Ca(2+)-transport ATPases of muscle, brain and blood platelets.
Mitidieri F; de Meis L
Biochem J; 1995 Dec; 312 ( Pt 3)(Pt 3):733-7. PubMed ID: 8554513
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
19. Structure/activity relationship of thapsigargin inhibition on the purified Golgi/secretory pathway Ca
Chen J; De Raeymaecker J; Hovgaard JB; Smaardijk S; Vandecaetsbeek I; Wuytack F; Møller JV; Eggermont J; De Maeyer M; Christensen SB; Vangheluwe P
J Biol Chem; 2017 Apr; 292(17):6938-6951. PubMed ID: 28264934
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis of five thapsigargins: guaianolide natural products exhibiting sub-nanomolar SERCA inhibition.
Andrews SP; Ball M; Wierschem F; Cleator E; Oliver S; Högenauer K; Simic O; Antonello A; Hünger U; Smith MD; Ley SV
Chemistry; 2007; 13(20):5688-712. PubMed ID: 17508363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
